Metformin × all-cause mortality

SynthesisOncotarget2017

Metformin is associated with survival benefit in pancreatic cancer patients with diabetes: a systematic review and meta-analysis.

Ping-Ting Zhou et al.PubMed ↗Full text ↗Publisher ↗

  • Metformin treatmentno clear effectLower overall survival.Nothing cleared the noise.

What the trial testedas reported · 2017

Not counted

Probably lowered overall survival

−16%−27% to −4%

metformin treatment vs non-metformin treatment

Bigger than 5 in 10 for all-cause mortality

As reported

HR 0.84, 95% CI 0.73–0.96

Who was studied, and how

people with type 2 diabetes, in this paper

The trial randomly assignedassigned by chance

metformin treatment
non-metformin treatment

Probably lowered overall survival−16%

randomised

the abstract, start to end

in both overall survival (OS) ([HR] 0.84; 95% confidence interval [CI]:

← favours treatmentfavours comparator →
could be chance
Overall survival (OS)metformin treatment vs non-metformin treatment
HR 0.840.73–0.96
MetforminAll-cause mortality
1 / 4

42 papers cite it

2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
this paperpooled itcites it
Full record →Abstract, authors, funding and every citing paper · PMID 28445955